Updated thresholds for alanine aminotransferase do not exclude significant histological disease in chronic hepatitis C

Liver International

Volumn 31, Issue 7, 2011, Pages 1039-1046

  Sanai, Faisal M ^a,b   Helmy, Ahmed ^c   Dale, Cheryl ^d   Al Ashgar, Hamad ^c   Abdo, Ayman A ^b,e   Katada, Kazuhiro ^d   AlMana, Hadeel ^c   Saadeh, Mayssa ^f   Al Hussaini, Hussa ^a   AlQuaiz, Mohammed ^c   Hashem, Ahmed ^g   AlSwat, Khalid ^b,e   Bzeizi, Khalid I ^a   Marotta, Paul J ^d  

^a Riyadh Military Hospital ^*  (Saudi Arabia)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^d LONDON HEALTH SCIENCES CENTRE   (Canada)

^e KING SAUD UNIVERSITY   (Saudi Arabia)

^f KING ABDULLAH INTERNATIONAL MEDICAL RESEARCH CENTER   (Saudi Arabia)

^g Saudi German Hospital   (Saudi Arabia)

Author keywords

Aminotransferase; Fibrosis; Hepatitis C virus; Histology; Necroinflammation

Indexed keywords

ALANINE AMINOTRANSFERASE;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FATTY LIVER; FEMALE; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER FIBROSIS; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; PREVALENCE;

ALANINE TRANSAMINASE; DISEASE PROGRESSION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LOGISTIC MODELS; MALE; ODDS RATIO; ROC CURVE;

EID: 79960088920     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02551.x     Document Type: Article

References (24)

1. Seeff LB, Hoofnagle JH. National Institutes of Health Consensus Development Conference: management of hepatitis C 2002. Hepatology 2002; 36 (Suppl. 1): S1-2.
2. Marcellin P. Hepatitis C: the clinical spectrum of the disease. J Hepatol 1999; 31: 9-16.
3. Yeo AET, Ghany M, Conry-Cantilena C, et al. Stability of HCV-RNA level and its lack of correlation with disease severity in asymptomatic chronic hepatitis C virus carriers. J Viral Hepat 2001; 8: 256-63.
4. Zeuzem S, Alberti A, Rosenberg W, et al. Review article: management of patients with chronic hepatitis C virus infection and 'normal' alanine aminotransferase activity. Aliment Pharmacol Ther 2006; 24: 1133-49.
5. Ahmed A, Keeffe EB. Chronic hepatitis C with normal aminotransferase levels. Gastroenterology 2004; 126: 1409-15.
6. Sanai FM, Benmousa A, Al-Hussaini H, et al. Is serum alanine transaminase level a reliable marker of histological disease in chronic hepatitis C infection? Liver Int 2008; 28: 1011-8.
7. Kyrlagkitsis I, Portmann B, Smith H, et al. Liver histology and progression of fibrosis in individuals with chronic hepatitis C and persistently normal ALT. Am J Gastroenterol 2003; 98: 1588-93.
8. Mathurin P, Moussalli J, Cadranel JF, et al. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology 1998; 27: 868-72.
9. Boccato S, Pistis R, Noventa F, et al. Fibrosis progression in initially mild chronic hepatitis C. J Viral Hepat 2006; 13: 297-302.
10. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002; 137: 1-10.
11. Ghany MG, Strader DB, Thomas DL, Seeff LB. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-74.
12. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994; 20: 15-20.
13. Kleiner DE, Brunt EM, Van Natta M, et al. Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-21.
14. Puoti C, Castellacci R, Montagnese F, et al. Histological and virological features and follow-up of hepatitis C virus carriers with normal aminotransferase levels: the Italian prospective study of the asymptomatic C carriers (ISACC). J Hepatol 2002; 37: 117-23.
15. Rumi MG, De Filippi F, Donato MF, et al. Progressive hepatic fibrosis in healthy carriers of hepatitis C virus with a transaminase breakthrough. J Viral Hepat 2002; 9: 71-4.
16. Rumi MG, De Filippi F, La Vecchia C, et al. Hepatitis C reactivation in patients with chronic infection with genotype 1b and 2c: a retrospective cohort study of 206 untreated patients. Gut 2005; 54: 402-6.
17. Zeuzem S, Diago M, Gane E, et al. Peginterferon alfa-2a (40KD) and ribavirin in patients with normal aminotransferase levels. Gastroenterology 2004; 127: 1724-32.
18. Massard J, Ratziu V, Thabut D, et al. Natural history and predictors of disease severity in chronic hepatitis C. J Hepatol 2006; 44 (Suppl.): S19-24.
19. Rubbia-Brandt L, Quadri R, Abid K, et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 2000; 33: 106-15.
20. Ratziu V, Munteanu M, LIDO Study Group et al. Fibrogenic impact of high serum glucose in chronic hepatitis C. J Hepatol 2003; 39: 1049-55.
21. Jamal MM, Soni A, Quinn PG, et al. Clinical features of hepatitis C-infected patients with persistently normal alanine transaminase levels in the Southwestern United States. Hepatology 1999; 30: 1307-11.
22. Pradat P, Alberti A, Poynard T, et al. Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study. Hepatology 2002; 36 (Part 1): 973-7.
23. Poynard T, Ratziu V, Charlotte F, et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001; 34: 730-9.
24. Deuffic-Burban S, Poynard T, Valleron AJ. Quantification of fibrosis progression in patients with chronic hepatitis C using a Markov model. J Viral Hepat 2002; 9: 114-22.